Gene · 970
Papers4,349
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 4,349
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Membrane-bound IL-15 co-expression powers a potent and persistent CD70-targeted TRuC T-cell therapy. | Front Immunol | 2025 | 40519930 | PubTator, text mining | PubMed |
| CAR-T cell therapy clinical trials: global progress, challenges, and future directions from ClinicalTrials.gov insights. | Front Immunol | 2025 | 40463393 | PubTator, text mining | PubMed |
Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II study. | Signal Transduct Target Ther | 2025 | 40404633 | PubTator, text mining | PubMed |
| IKBKB gain of function: An inborn error with clinical heterogeneity progressing toward combined immunodeficiency. | J Allergy Clin Immunol | 2025 | 40403933 | PubTator, text mining | PubMed |
| The CD70-CD27 Axis in Cancer Immunotherapy: Predictive Biomarker and Therapeutic Target. | Clin Cancer Res | 2025 | 40388162 | PubTator, text mining | PubMed |
| Insights into sepsis-induced apoptosis: Interplay between programmed cell death and interleukin-7. | J Crit Care Med (Targu Mures) | 2025 | 40386708 | PubTator, text mining | PubMed |
| Chimeric antigen receptor-macrophages: Emerging next-generation cell therapy for brain cancer. | Neurooncol Adv | 2025 | 40376682 | PubTator, text mining | PubMed |
| Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements. | J Transl Med | 2025 | 40369674 | PubTator, text mining | PubMed |
| Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR T cells. | Blood | 2025 | 40359480 | PubTator, text mining | PubMed |
| Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma. | Biomark Res | 2025 | 40312353 | PubTator, text mining | PubMed |
| CD70-Targeted [18F]RCCB6 Immuno-PET/CT Imaging in Patients with Nasopharyngeal Carcinoma: A Proof-of-Concept Study. | J Nucl Med | 2025 | 40306966 | PubTator, text mining | PubMed |
| CD70-targeted cancer theranostics: Progress and challenges. | Med | 2025 | 40250430 | PubTator, text mining | PubMed |
| Regulation mechanism of chemokine CXCL3 in nasopharyngeal carcinoma. | Pathol Res Pract | 2025 | 40239601 | PubTator, text mining | PubMed |
| CD70 recruitment to the immunological synapse is dependent on CD20 in B cells. | Proc Natl Acad Sci U S A | 2025 | 40232798 | PubTator, text mining | PubMed |
| Expression of costimulatory molecule CD70 is prognostic in small cell lung cancer. | Cancer Immunol Immunother | 2025 | 40205178 | PubTator, text mining | PubMed |
| Sodium citrate pretreatment enhances CAR-T cell persistence and anti-tumor efficacy through inhibition of calcium signaling. | Front Immunol | 2025 | 40165944 | PubTator, text mining | PubMed |
| Advancing CRISPR genome editing into gene therapy clinical trials: progress and future prospects. | Expert Rev Mol Med | 2025 | 40160040 | PubTator, text mining | PubMed |
| Soluble CD27 differentially predicts resistance to anti-PD1 alone but not with anti-CTLA-4 in melanoma. | EMBO Mol Med | 2025 | 40148586 | PubTator, text mining | PubMed |
| Comprehensive pan-cancer analysis reveals CD70 as a promising therapeutic target and biomarker in clear cell renal cell carcinoma. | Int J Biol Macromol | 2025 | 40113005 | PubTator, text mining | PubMed |
| Antigen-presenting fibroblasts: emerging players in immune modulation and therapeutic targets. | Theranostics | 2025 | 40093895 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/970/papers?page=11